Chinese Academy of Sciences' Cash Capital put up a share of the funds for oncological drug developer OnQuality Pharmaceuticals' first funding round.
OnQuality Pharmaceuticals, a China-based developer of drugs to counteract chemotherapy side effects, has obtained $15m in an inaugural round backed by Cash Capital, an investment arm of Chinese Academy of Sciences, according to PharmaPhorum.
The round was co-led by venture firm Matrix Partners China and investment firm BioTrack Capital.
Founded in 2018, OnQuality Pharmaceuticals is working on drugs for patients undergoing cancer treatment which lessen side effects associated with existing medications.
The company’s lead asset, OQL011, would…
